Clinical data supporting mechanism of action reinforce potential as a novel cancer treatment ...

The city council on Monday will review the city's annual audit and is expected to vote on a report submitted to Housing and ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Adoption of the audited Annual Report 2024 The audited 2024 Annual Report was adopted. Presentation of the Remuneration Report ... Pandora is the world's largest jewellery brand, specialising in the ...

Enrollment ongoing in Phase 2 KOURAGE trial of AuxoraTM in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 ...

This week’s Edmonds City Council meeting, while short on action items, was taken up with a series of reports providing ...

City council is eyeing a new end-of-year report system. In a meeting of the committee of the whole Tuesday, Councilwoman Sara Baer presented the other members of city council with an end-of-year ...

BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of ...

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327 ...